Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16

The Burden of Influenza-Associated Hospitalizations in Oman, January 2008-June 2013

(2015) Salah Al-Awaidy et al.   PLoS One

Bacillus Calmette-Guérin (BCG) Vaccine Adverse Events in Victoria, Australia: Analysis of Reports to an Enhanced Passive Surveillance System

(2014) Hazel J. Clothier et al.   DRUG SAFETY

Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China

(2011) Xiao-Feng Liang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010

(2010) Claudia Vellozzi et al.   VACCINE

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

(2009) Claudia Vellozzi et al.   VACCINE

Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season

(2009) Ian G. Barr et al.   VACCINE

Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses

(2008) Colin A. Russell et al.   VACCINE